BiomX (NYSEMKT:PHGE) Trading Up 154.4% – Here’s Why

BiomX Inc. (NYSEMKT:PHGE)’s stock price shot up 154.4% on Tuesday . The stock traded as high as $0.7762 and last traded at $1.88. 53,300 shares were traded during mid-day trading, a decline of 85% from the average session volume of 347,190 shares. The stock had previously closed at $0.7390.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, BiomX has an average rating of “Buy” and an average target price of $399.00.

BiomX Trading Up 151.0%

The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $2.83 million, a P/E ratio of -2.47 and a beta of 1.56. The business has a fifty day moving average price of $5.24 and a 200 day moving average price of $7.95.

Hedge Funds Weigh In On BiomX

Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in BiomX in the 3rd quarter valued at $85,000. Allostery Investments LP increased its holdings in shares of BiomX by 46.1% in the first quarter. Allostery Investments LP now owns 940,629 shares of the company’s stock valued at $523,000 after purchasing an additional 296,796 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of BiomX in the first quarter valued at about $166,000. Finally, Alyeska Investment Group L.P. lifted its stake in shares of BiomX by 83.8% during the 1st quarter. Alyeska Investment Group L.P. now owns 1,590,738 shares of the company’s stock worth $884,000 after buying an additional 725,338 shares during the last quarter. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Ltd. is a clinical-stage biotechnology company developing targeted bacteriophage therapies designed to modulate the human microbiome. The company’s proprietary platform combines computational analytics with phage biology to identify and engineer virus-based agents that selectively target disease-associated bacteria without disrupting beneficial microbial communities. Through this precision approach, BiomX aims to address unmet needs in gastrointestinal and dermatological disorders driven by microbial dysbiosis.

BiomX’s pipeline includes investigational products for conditions such as Crohn’s disease, ulcerative colitis and acne.